Drug used to treat heavy periods will stop trauma patients bleeding to death

Jan 19, 2011

Tranexamic acid (TXA), a drug used to treat heavy menstrual periods, could save the lives of tens of thousands of bleeding accident victims each year and reduce combat deaths, say Cochrane researchers. The researchers carried out a systematic review of trials examining the effectiveness of tranexamic acid (TXA) in patients with bleeding after severe injury.

TXA is an inexpensive drug that reduces clot breakdown. It has been used for many years to reduce heavy menstrual and is often given during planned surgery to reduce the need for . However, more recently, tranexamic acid has been tested in bleeding . Of such patients who die in hospital, nearly half die due to excessive blood loss and most others die from injuries that are worsened by bleeding.

According to the results of the new review, TXA reduces the risk of death in injured patients with severe bleeding by about 10% compared to giving no treatment, which equates to saving over 70,000 lives each year if TXA was used worldwide. The results are based on one large trial involving 20,211 patients and one small trial in 240 patients, both carried out since an earlier, inconclusive review in 2004.

Lead researcher Ian Roberts of the London School of Hygiene & Tropical Medicine in London, UK, said, "TXA reduces the risk of a patient bleeding to death following an injury and appears to have few side effects. It could save lives in both civilian and military settings."

"These results are based on a large number of patients (men and women) who came from many different countries. Given the high quality of the evidence for the benefits of this drug, we recommend it be used more widely in injury victims with bleeding."

A separate Cochrane Systematic Review focused on trials of TXA and other similar drugs in people scheduled for non-urgent surgery showed that TXA was highly effective at reducing and the need for red blood cell transfusion.

Explore further: Researcher develops, proves effectiveness of new drug for spinal muscular atrophy

add to favorites email to friend print save as pdf

Related Stories

Aprotinin associated with increased risk of death

May 14, 2008

Aprotinin is associated with a 50 per cent increase in the relative risk of death, according to a major Canadian clinical trial comparing three drugs routinely used to prevent blood loss during heart surgery. The trial, published ...

British troops get untested drug

Sep 18, 2006

British troops in Iraq and Afghanistan are being treated with an experimental blood-clotting drug that has not been fully tested, it was reported Saturday.

Recommended for you

A novel therapy for sepsis?

14 hours ago

A University of Tokyo research group has discovered that pentatraxin 3 (PTX3), a protein that helps the innate immune system target invaders such as bacteria and viruses, can reduce mortality of mice suffering ...

Cellular protein may be key to longevity

Sep 15, 2014

Researchers have found that levels of a regulatory protein called ATF4, and the corresponding levels of the molecules whose expression it controls, are elevated in the livers of mice exposed to multiple interventions ...

Gut bacteria tire out T cells

Sep 15, 2014

Leaky intestines may cripple bacteria-fighting immune cells in patients with a rare hereditary disease, according to a study by researchers in Lausanne, Switzerland. The study, published in The Journal of Experimental Me ...

User comments : 0